Compare Davita Inc (DVA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs BIO-TECHNE Corp — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Davita Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and BIO-TECHNE Corp for 64 Days on average.
| DVA | TECH | |
|---|---|---|
Market Cap | $11.29B | $11.36B |
Volume | 582,204 | 5,390,331 |
Sector | Health | Health |
52-Week High | $240.96 | $72.61 |
52-Week Low | $103.87 | $43.31 |
Typical Hold Time | 114 Days | 64 Days |
Enterprise Value | $24.01B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, up 0.14% with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 32.36% gross margins and 635.3% ROE, though net income margin declined to 5.47% in 2025. Recent partnership expansions with Humana for value-based kidney care and institutional buying by BlackRock provide positive catalysts. Valuation appears reasonable with P/E of 15 and P/S of 0.88, below sector averages.
Outlook remains mixed with analyst consensus target of $235.67 suggesting 33% upside, but technical indicators signal near-term caution. Key risks include regulatory pressures on healthcare reimbursements and rising debt-to-asset ratio reaching 65.55%. Earnings momentum from three consecutive quarterly beats supports fundamental strength, though margin compression warrants monitoring.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, as the stock approaches its 52-week high of $72.70. The company shows strong profitability with 65.77% gross margins and 14.97% net income margin, though earnings have been mixed with one miss and two beats in recent quarters. Technical indicators show a bullish trend with support at $72 and resistance at $73. Recent news highlights shareholder approval of the Merck KGaA acquisition at $73 per share, providing a clear near-term catalyst.
The acquisition premium offers limited upside from current levels, while fundamental metrics show elevated valuation (P/E 62.46) despite solid profitability. Key risks include integration challenges post-acquisition and potential regulatory scrutiny. Analyst consensus leans neutral with 46% buy ratings and a $65.78 price target below current trading levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
